Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis
by Laetitia Pouzol, MSc, PharmD; Luca Piali, PhD; Claude CA Bernard, PhD; Marianne M. Martinic, PhD; Beat Steiner, PhD; and Martine Clozel, MD Drs. Pouzol and Clozel were with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research, and are presently with Idorsia Pharmaceuticals Ltd. in Allschwil, Switzerland. Dr. Piali was with […]
The post Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis appeared first on Innovations in Clinical Neuroscience.
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: ICNS Online Editor Tags: Current Issue Multiple Sclerosis Original Research combination therapy dimethyl fumarate (DMF) disease activity Experimental autoimmune encephalomyelitis (EAE) multiple sclerosis (MS) sphingosine-1-phosphate Source Type: research
More News: Autoimmune Disease | Brain | Multiple Sclerosis | Neurology | Neuroscience | Switzerland Health